Recently, the Ministry of Agriculture and Rural Affairs issued Announcement No. 957, approving the supplementary registration of Nosiheptide premix declared by Zhejiang Esigma Biotechnology Co., Ltd., and officially allowing the product to be used in layer hen production. This important supplement provides a new solution for controlling clostridial diseases in layer hens, and the feature of zero egg withdrawal period has become the focus of the industry.

Announcement Content: Nosiheptide Premix Approved for Layer Hens

In accordance with Announcement No. 957 of the Ministry of Agriculture and Rural Affairs of the People's Republic of China, the supplementary registration of Nosiheptide premix declared by Zhejiang Esigma Biotechnology Co., Ltd. has been approved. The announcement came into effect on October 10, 2025, and was officially released on October 11.

As clearly stated in the attached "Catalog of Supplementary Registrations of Veterinary Drugs" of the announcement, the supplementary registration item of Nosiheptide premix is "adding layer hens as the target animal," and a 3-year monitoring period has been set for this supplementary item. This means that the scope of application of Nosiheptide premix has been officially expanded to layer hens, providing a new disease control tool for the layer hen breeding industry.

Addressing Industry Pain Points: Effectively Controlling Clostridial Diseases

Chicken necrotic enteritis caused by Clostridium perfringens is widely distributed in China and is one of the most harmful diseases in the poultry industry. Especially after the ban on antibiotics in feed, the incidence of this disease has shown an unfavorable trend of increasing year by year. Chicken necrotic enteritis can occur in both broilers and layer hens, and there is no seasonal restriction. In layer hens, the disease is more common in chicks and pullets, causing digestive tract symptoms such as diarrhea and hematochezia, affecting the laying rate and egg quality of layer hens, and leading to an increase in the mortality and culling rate of layer hens.

As a sulfur-containing polypeptide antibiotic, Nosiheptide is effective against most Gram-positive bacteria, with the most significant effects on Staphylococcus, Streptococcus, and Clostridium perfringens, and also effective against a few Gram-negative bacteria. In 2023, Nosiheptide premix was approved for marketing as a therapeutic drug. After two years of market application, Nosiheptide has achieved remarkable results in controlling clostridium-induced intestinal diseases in broilers. In the layer hen market, clostridial enteritis has long been an industry pain point. The approval of Nosiheptide premix for layer hens provides a new solution for controlling intestinal diseases in layer hens and ensuring their health.

Major Breakthrough: Zero Egg Withdrawal Period

A groundbreaking advantage of Nosiheptide premix for layer hens is its zero egg withdrawal period. This feature brings enormous convenience and economic benefits to layer hen farmers. In traditional layer hen breeding, the use of drugs for disease prevention and treatment usually requires a certain egg withdrawal period, during which the eggs produced cannot be sold on the market, resulting in economic losses for farmers. The zero egg withdrawal period of Nosiheptide premix completely solves this problem, allowing farmers to treat layer hen diseases without affecting the normal sales of eggs.

Technological Leadership: Huineng's R&D Journey of Nosiheptide

Zhejiang Esigma has profound accumulation in Nosiheptide R&D and is the first enterprise in China and the second in the world to possess independent intellectual property rights of Nosiheptide. Dr. Chen Guicai, Chairman of the company, holds a PhD in Biology from Zhejiang University and was a postdoctoral fellow at Harvard Medical School in the United States. He presided over the formulation of the national standard for "Nosiheptide" and applied for more than ten related invention patents. In 2010, the Nosiheptide project won the first-class Zhejiang Provincial Science and Technology Award (with Esigma as the first completing unit), and in 2011, the Nosiheptide product obtained the National Key New Product Certificate.

Over the years, Esigma has always adhered to the core concept of "strengthening independent innovation and taking the brand road." By increasing R&D investment, carrying out industry-university-research cooperation, and establishing R&D platforms, the company has actively enhanced and maintained its independent innovation capabilities.

Environmental Protection and Safety: Low Dosage, Non-Absorbable, No Residues

Nosiheptide is a new type of non-absorbable drug exclusively for animals. With a large molecular weight, it is not absorbed by the gastrointestinal tract. After exerting its effect in the intestines, it is excreted with feces, making it difficult to remain in animal tissues. It has the characteristics of low dosage, safety, non-absorption, and no residues, fully meeting the medication safety requirements of layer hens and having broad application prospects in layer hen breeding.

The approval of Nosiheptide premix for layer hens and the realization of zero egg withdrawal period are the result of Zhejiang Esigma Biotechnology Co., Ltd.'s more than 20 years of persistence and innovation. With the promotion and application of Nosiheptide premix in layer hen breeding, the prevention and control of clostridial diseases in layer hens will be more efficient, the breeding cost is expected to be further reduced, and it will provide new technical support for ensuring the safety and stable supply of egg products in China.